A large amount of cell-based therapies are hindered by shortfalls in manufacturing. A key issue is the inability to produce adherent stem cells in the quality, quantity and safety level necessary to bring them to clinical trials. denovoMATRIX directly tackles these challenges in cell manufacturing, with its proprietary coating technology which enables the production of adherent stem cells in the quality, quantity and safety level necessary.